Article ; Online: Bevacizumab for Retinopathy of Prematurity: 2-Year Neurodevelopmental Follow-up.
American journal of perinatology
2020 Volume 38, Issue 11, Page(s) 1158–1166
Abstract: Objective: This study aimed to determine whether infants who were treated with intravitreal bevacizumab (IVB) for retinopathy of prematurity (ROP) were at higher risk of death or neurodevelopmental impairment (NDI) when compared with infants who were ... ...
| Abstract | Objective: This study aimed to determine whether infants who were treated with intravitreal bevacizumab (IVB) for retinopathy of prematurity (ROP) were at higher risk of death or neurodevelopmental impairment (NDI) when compared with infants who were not treated with IVB (Laser only). Study design: This retrospective study included 146 infants born from 2009 through 2016 with a birth weight (BW) <1,000 g, gestational age <27 weeks, and required ROP therapy. Death and NDI rates were assessed at 18 to 24 months' corrected age. Results: Rates of death or severe NDI were 62 and 53% in the IVB ( Conclusion: Bevacizumab therapy for ROP did not affect survival and neurodevelopment of extremely preterm infants. Key points: · Intravitreal bevacizumab therapy for retinopathy of prematurity may be safe in periviable preterm infants.. · Intravitreal bevacizumab therapy does not increase mortality rate in periviable preterm infants.. · Intravitreal bevacizumab therapy does not increase adverse neurodevelopmental outcome in periviable infants.. |
|---|---|
| MeSH term(s) | Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Angiogenesis Inhibitors/therapeutic use ; Bevacizumab/administration & dosage ; Bevacizumab/adverse effects ; Bevacizumab/therapeutic use ; Child Development/drug effects ; Child, Preschool ; Female ; Follow-Up Studies ; Humans ; Infant ; Infant, Extremely Low Birth Weight ; Infant, Extremely Premature ; Infant, Newborn ; Intellectual Disability/etiology ; Intravitreal Injections ; Laser Therapy/adverse effects ; Logistic Models ; Male ; Retinopathy of Prematurity/drug therapy ; Retinopathy of Prematurity/mortality ; Retrospective Studies |
| Chemical Substances | Angiogenesis Inhibitors ; Bevacizumab (2S9ZZM9Q9V) |
| Language | English |
| Publishing date | 2020-05-23 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 605671-4 |
| ISSN | 1098-8785 ; 0735-1631 |
| ISSN (online) | 1098-8785 |
| ISSN | 0735-1631 |
| DOI | 10.1055/s-0040-1710556 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1929: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.